Skye Bioscience
SKYE
About: Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Employees: 16
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
117% more capital invested
Capital invested by funds: $39.3M [Q1] → $85.3M (+$46M) [Q2]
111% more call options, than puts
Call options by funds: $388K | Put options by funds: $184K
13.87% less ownership
Funds ownership: 79.73% [Q1] → 65.86% (-13.87%) [Q2]
19% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 16
24% less funds holding
Funds holding: 75 [Q1] → 57 (-18) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
59% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 29
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Evercore ISI Group
Michael DiFiore
|
$10
|
Outperform
Initiated
|
15 Aug 2025 |
|
JMP Securities
Jonathan Wolleben
|
$15
|
Market Outperform
Reiterated
|
24 Jun 2025 |
Financial journalist opinion
Based on 7 articles about SKYE published over the past 30 days
